AI Article Synopsis
- The novel coronavirus SARS-CoV-2 emerged in December 2019, quickly leading to millions of infections and over a million deaths worldwide.
- Various companies and research institutions have since been working to develop vaccines, including traditional and innovative options like mRNA and DNA vaccines.
- This review will focus on some of the top non-viral vaccines in clinical development and explore strategies to enhance their effectiveness, safety, and accessibility for mass vaccination.
Article Abstract
The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vaccine exhibits a different potency and duration of efficacy, as determined by the antigen design, adjuvant molecules, vaccine delivery platforms, and immunization method. In this review, we will introduce a few of the leading non-viral vaccines that are under clinical stage development and discuss delivery strategies to improve vaccine efficacy, duration of protection, safety, and mass vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744276 | PMC |
| http://dx.doi.org/10.1016/j.addr.2020.12.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!